Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Felipe J S Jones, Paula R Sanches, Jason R Smith, Sahar F Zafar, Deborah Blacker, John Hsu, Lee H Schwamm, Joseph P Newhouse, Michael B Westover, Lidia M V R Moura
Importance: Limited evidence is available concerning optimal seizure prophylaxis after spontaneous intracerebral hemorrhage (sICH). Objective: To evaluate which of 4 seizure prophylaxis strategies provides the greatest net benefit for patients with sICH. Design, Setting, and Participants: This decision analysis used models to simulate the following 4 common scenarios: (1) a 60-year-old man with low risk of early (≤7 days after stroke) (10%) and late (3...
July 26, 2021: JAMA Neurology
#2
Jean-Claude Baron
No abstract text is available yet for this article.
July 26, 2021: JAMA Neurology
#3
Michelle M Mielke, Ryan D Frank, Jeffrey L Dage, Andreas Jeromin, Nicholas J Ashton, Kaj Blennow, Thomas K Karikari, Eugene Vanmechelen, Henrik Zetterberg, Alicia Algeciras-Schimnich, David S Knopman, Val Lowe, Guojun Bu, Prashanthi Vemuri, Jonathan Graff-Radford, Clifford R Jack, Ronald C Petersen
Importance: Cerebrospinal fluid phosphorylated tau (p-tau) 181, p-tau217, and p-tau231 are associated with neuropathological outcomes, but a comparison of these p-tau isoforms in blood samples is needed. Objective: To conduct a head-to-head comparison of plasma p-tau181 and p-tau231 measured on the single-molecule array (Simoa) platform and p-tau181 and p-tau217 measured on the Meso Scale Discovery (MSD) platform on amyloid and tau positron emission tomography (PET) measures, neurodegeneration, vascular pathology, and cognitive outcomes...
July 26, 2021: JAMA Neurology
#4
Hector H Garcia, Armando E Gonzalez, Robert H Gilman
No abstract text is available yet for this article.
July 26, 2021: JAMA Neurology
#5
Gregory W Albers, Maarten G Lansberg, Scott Brown, Ashutosh P Jadhav, Diogo C Haussen, Sheila O Martins, Leticia C Rebello, Andrew M Demchuk, Mayank Goyal, Marc Ribo, Aquilla S Turk, David S Liebeskind, Jeremy J Heit, Michael P Marks, Tudor G Jovin, Raul G Nogueira
Importance: The optimal imaging approach for identifying patients who may benefit from endovascular thrombectomy (EVT) beyond 6 hours after they were last known well is unclear. Six randomized clinical trials (RCTs) have evaluated the efficacy of EVT vs standard medical care among patients with ischemic stroke. Objective: To assess the benefits of EVT among patients with 3 baseline imaging profiles using a pooled analysis of RCTs. Data Sources: The AURORA (Analysis of Pooled Data from Randomized Studies of Thrombectomy More Than 6 Hours After Last Known Well) Collaboration pooled patient-level data from the included clinical trials...
July 26, 2021: JAMA Neurology
#6
David S Knopman
No abstract text is available yet for this article.
July 19, 2021: JAMA Neurology
#7
Esther L Yuh, Sonia Jain, Xiaoying Sun, Dana Pisica, Mark H Harris, Sabrina R Taylor, Amy J Markowitz, Pratik Mukherjee, Jan Verheyden, Joseph T Giacino, Harvey S Levin, Michael McCrea, Murray B Stein, Nancy R Temkin, Ramon Diaz-Arrastia, Claudia S Robertson, Hester F Lingsma, David O Okonkwo, Andrew I R Maas, Geoffrey T Manley, Opeolu Adeoye, Neeraj Badjatia, Kim Boase, Yelena Bodien, John D Corrigan, Karen Crawford, Sureyya Dikmen, Ann-Christine Duhaime, Richard Ellenbogen, V Ramana Feeser, Adam R Ferguson, Brandon Foreman, Raquel Gardner, Etienne Gaudette, Luis Gonzalez, Shankar Gopinath, Rao Gullapalli, J Claude Hemphill, Gillian Hotz, C Dirk Keene, Joel Kramer, Natalie Kreitzer, Chris Lindsell, Joan Machamer, Christopher Madden, Alastair Martin, Thomas McAllister, Randall Merchant, Lindsay Nelson, Laura B Ngwenya, Florence Noel, Amber Nolan, Eva Palacios, Daniel Perl, Miri Rabinowitz, Jonathan Rosand, Angelle Sander, Gabriella Satris, David Schnyer, Seth Seabury, Arthur Toga, Alex Valadka, Mary Vassar, Ross Zafonte
Importance: A head computed tomography (CT) with positive results for acute intracranial hemorrhage is the gold-standard diagnostic biomarker for acute traumatic brain injury (TBI). In moderate to severe TBI (Glasgow Coma Scale [GCS] scores 3-12), some CT features have been shown to be associated with outcomes. In mild TBI (mTBI; GCS scores 13-15), distribution and co-occurrence of pathological CT features and their prognostic importance are not well understood. Objective: To identify pathological CT features associated with adverse outcomes after mTBI...
July 19, 2021: JAMA Neurology
#8
Beke Esther Linnemann, Alexander Neumann, Iakov Shimanovich
No abstract text is available yet for this article.
July 19, 2021: JAMA Neurology
#9
Stevie Hendriks, Kirsten Peetoom, Christian Bakker, Wiesje M van der Flier, Janne M Papma, Raymond Koopmans, Frans R J Verhey, Marjolein de Vugt, Sebastian Köhler, Adrienne Withall, Juliette L Parlevliet, Özgül Uysal-Bozkir, Roger C Gibson, Susanne M Neita, Thomas Rune Nielsen, Lise C Salem, Jenny Nyberg, Marcos Antonio Lopes, Jacqueline C Dominguez, Ma Fe De Guzman, Alexander Egeberg, Kylie Radford, Tony Broe, Mythily Subramaniam, Edimansyah Abdin, Amalia C Bruni, Raffaele Di Lorenzo, Kate Smith, Leon Flicker, Merel O Mol, Maria Basta, Doris Yu, Golden Masika, Maria S Petersen, Luis Ruano
Importance: Reliable prevalence estimates are lacking for young-onset dementia (YOD), in which symptoms of dementia start before the age of 65 years. Such estimates are needed for policy makers to organize appropriate health care. Objective: To determine the global prevalence of YOD. Data Sources: The PubMed, Embase, CINAHL, and PsycInfo databases were systematically searched for population-based studies on the prevalence of YOD published between January 1, 1990, and March 31, 2020...
July 19, 2021: JAMA Neurology
#10
(no author information available yet)
No abstract text is available yet for this article.
July 12, 2021: JAMA Neurology
#11
Catarina Fernandes, Isabel Taveira, Hipólito Nzwalo
No abstract text is available yet for this article.
July 12, 2021: JAMA Neurology
#12
Yan Liu, Jing Luo, Fei Xiao
No abstract text is available yet for this article.
July 12, 2021: JAMA Neurology
#13
Yongjun Wang, Yuesong Pan, Hao Li, Pierre Amarenco, Hans Denison, Scott R Evans, Anders Himmelmann, Stefan James, Filip Birve, Per Ladenvall, Carlos A Molina, S Claiborne Johnston
Importance: Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These patients were included in the Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial, but results have not been reported separately, raising concerns about safety and efficacy in this subgroup. Objective: To evaluate the efficacy and safety of ticagrelor plus aspirin in patients with moderate ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score of 4 to 5)...
July 9, 2021: JAMA Neurology
#14
Cynthia A Lemere, Elizabeth Head, David M Holtzman
No abstract text is available yet for this article.
July 6, 2021: JAMA Neurology
#15
Pierre Seners, Jean-Claude Baron, Guillaume Turc
No abstract text is available yet for this article.
July 6, 2021: JAMA Neurology
#16
Johanna M Ospel, Bijoy K Menon, Mayank Goyal
No abstract text is available yet for this article.
July 6, 2021: JAMA Neurology
#17
Michael A McCrea, Joseph T Giacino, Jason Barber, Nancy R Temkin, Lindsay D Nelson, Harvey S Levin, Sureyya Dikmen, Murray Stein, Yelena G Bodien, Kim Boase, Sabrina R Taylor, Mary Vassar, Pratik Mukherjee, Claudia Robertson, Ramon Diaz-Arrastia, David O Okonkwo, Amy J Markowitz, Geoffrey T Manley, Opeolu Adeoye, Neeraj Badjatia, M Ross Bullock, Randall Chesnut, John D Corrigan, Karen Crawford, Ann-Christine Duhaime, Richard Ellenbogen, V Ramana Feeser, Adam R Ferguson, Brandon Foreman, Raquel Gardner, Etienne Gaudette, Dana Goldman, Luis Gonzalez, Shankar Gopinath, Rao Gullapalli, J Claude Hemphill, Gillian Hotz, Sonia Jain, C Dirk Keene, Frederick K Korley, Joel Kramer, Natalie Kreitzer, Chris Lindsell, Joan Machamer, Christopher Madden, Alastair Martin, Thomas McAllister, Randall Merchant, Laura B Ngwenya, Florence Noel, Amber Nolan, Eva Palacios, Daniel Perl, Ava Puccio, Miri Rabinowitz, Jonathan Rosand, Angelle Sander, Gabriella Satris, David Schnyer, Seth Seabury, Mark Sherer, Arthur Toga, Alex Valadka, Kevin Wang, John K Yue, Esther Yuh, Ross Zafonte
Importance: Moderate to severe traumatic brain injury (msTBI) is a major cause of death and disability in the US and worldwide. Few studies have enabled prospective, longitudinal outcome data collection from the acute to chronic phases of recovery after msTBI. Objective: To prospectively assess outcomes in major areas of life function at 2 weeks and 3, 6, and 12 months after msTBI. Design, Setting, and Participants: This cohort study, as part of the Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) study, was conducted at 18 level 1 trauma centers in the US from February 2014 to August 2018 and prospectively assessed longitudinal outcomes, with follow-up to 12 months postinjury...
July 6, 2021: JAMA Neurology
#18
Alexandre Bejanin, Maria Florencia Iulita, Eduard Vilaplana, Maria Carmona-Iragui, Bessy Benejam, Laura Videla, Isabel Barroeta, Susana Fernandez, Miren Altuna, Jordi Pegueroles, Victor Montal, Silvia Valldeneu, Sandra Giménez, Sofía González-Ortiz, Laia Muñoz, Concepción Padilla, Mateus Rozalem Aranha, Teresa Estellés, Ignacio Illán-Gala, Olivia Belbin, Valle Camacho, Liam Reese Wilson, Tiina Annus, Ricardo S Osorio, Sebastián Videla, Sylvain Lehmann, Anthony J Holland, Henrik Zetterberg, Kaj Blennow, Daniel Alcolea, Jordi Clarimon, Shahid H Zaman, Rafael Blesa, Alberto Lleó, Juan Fortea
Importance: Alzheimer disease (AD) is the leading cause of death in individuals with Down syndrome (DS). Previous studies have suggested that the APOE ɛ4 allele plays a role in the risk and age at onset of dementia in DS; however, data on in vivo biomarkers remain scarce. Objective: To investigate the association of the APOE ɛ4 allele with clinical and multimodal biomarkers of AD in adults with DS. Design, Setting, and Participants: This dual-center cohort study recruited adults with DS in Barcelona, Spain, and in Cambridge, UK, between June 1, 2009, and February 28, 2020...
July 6, 2021: JAMA Neurology
#19
Nina Xie, Jinxia Yang, Qiying Sun
No abstract text is available yet for this article.
June 28, 2021: JAMA Neurology
#20
Rik Ossenkoppele, Ruben Smith, Niklas Mattsson-Carlgren, Colin Groot, Antoine Leuzy, Olof Strandberg, Sebastian Palmqvist, Tomas Olsson, Jonas Jögi, Erik Stormrud, Hanna Cho, Young Hoon Ryu, Jae Yong Choi, Adam L Boxer, Maria L Gorno-Tempini, Bruce L Miller, David Soleimani-Meigooni, Leonardo Iaccarino, Renaud La Joie, Suzanne Baker, Edilio Borroni, Gregory Klein, Michael J Pontecorvo, Michael D Devous, William J Jagust, Chul Hyoung Lyoo, Gil D Rabinovici, Oskar Hansson
Importance: Tau positron emission tomography (PET) tracers have proven useful for the differential diagnosis of dementia, but their utility for predicting cognitive change is unclear. Objective: To examine the prognostic accuracy of baseline fluorine 18 (18F)-flortaucipir and [18F]RO948 (tau) PET in individuals across the Alzheimer disease (AD) clinical spectrum and to perform a head-to-head comparison against established magnetic resonance imaging (MRI) and amyloid PET markers...
June 28, 2021: JAMA Neurology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
